(2026). Soluble ST2 as a biomarker for predicting severe adverse events among pediatric patients with Mycoplasma pneumoniae pneumonia. PLOS ONE.
Successfully copied to clipboard
Copying to clipboard failed
Chicago Style (17th ed.) Citation
"Soluble ST2 as a Biomarker for Predicting Severe Adverse Events Among Pediatric Patients with Mycoplasma Pneumoniae Pneumonia."
PLOS ONE 2026.
Successfully copied to clipboard
Copying to clipboard failed
MLA (9th ed.) Citation
"Soluble ST2 as a Biomarker for Predicting Severe Adverse Events Among Pediatric Patients with Mycoplasma Pneumoniae Pneumonia."
PLOS ONE, 2026.
Successfully copied to clipboard
Copying to clipboard failed
Warning: These citations may not always be 100% accurate.